Research programme: dry eye syndrome gene therapy - Clear Solutions Biotech/Laboratorios Sophia
Latest Information Update: 06 Sep 2006
At a glance
- Originator Clear Solutions Biotech; Laboratorios Sophia
- Developer Clear Solutions Biotech
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Dry eyes
Most Recent Events
- 06 Sep 2006 Discontinued - Preclinical for Dry eyes in USA (unspecified route)
- 28 Apr 2000 New profile
- 28 Apr 2000 Preclinical development for Dry eyes in USA (Unknown route)